Humulin S (Soluble) (Insulin Human (Rdna))

Humulin S is indicated for the treatment of hyperglycemia in patients with diabetes mellitus.

• Type 1 diabetes mellitus as basal insulin replacement
• Type 2 diabetes mellitus when oral agents are insufficient
• Adjunct to diet and exercise for glycemic control
• Intravenous infusion in hospital settings for rapid glucose lowering
• Use in pediatric patients with type 1 diabetes
• Use as part of a basal‑bolus insulin regimen

• Humulin S delivers recombinant human insulin that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers the intrinsic tyrosine kinase pathway, promoting translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake. It also stimulates glycogen synthase, enhancing glycogen storage, and suppresses hepatic gluconeogenesis, thereby lowering circulating blood glucose levels. The overall effect is a rapid reduction in plasma glucose concentration after administration.

Adverse reactions to Humulin S may vary in frequency and severity.

Common

• Hypoglycemia (low blood glucose)
• Pain, redness, or swelling at the injection site
• Lipodystrophy (localized fat accumulation or loss)
• Weight gain
• Mild allergic skin reactions such as rash or itching

Serious

• Severe hypoglycemia with neuroglycopenic symptoms
• Anaphylactic or severe systemic allergic reaction
• Edema or fluid retention leading to heart failure

When prescribing Humulin S, clinicians should consider several safety factors.

• Regular monitoring of blood glucose to adjust dose as needed
• Caution in patients with hypoglycemia unawareness or frequent episodes
• Dose adjustments may be required during acute illness, surgery, or changes in physical activity
• Use carefully in renal or hepatic impairment because insulin clearance may be reduced
• Pregnancy and lactation safety data are limited; evaluate risk‑benefit before use
• Ensure proper storage (refrigerated, protect from light) and discard after the indicated in‑use period

Humulin S can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Non‑selective beta‑blockers, which may mask hypoglycemia symptoms
• Monoamine oxidase (MAO) inhibitors, which can potentiate insulin’s glucose‑lowering effect
• Thiazide diuretics, which may increase blood glucose levels

Use with caution

• Systemic glucocorticoids, which raise blood glucose and may require higher insulin doses
• Recombinant human growth hormone, which can reduce insulin sensitivity
• ACE inhibitors or angiotensin‑II receptor blockers, which may enhance insulin sensitivity and increase risk of hypoglycemia
• Alcohol consumption, especially in excess, which can cause delayed hypoglycemia